Middle East Respiratory Syndrome (MERS) is viral respiratory illness that was recently recognized in humans. It was first reported in Saudi Arabia in 2012 and has since spread to several other countries. Most people, identified as infected with MERS coronavirus (MERS-CoV), developed severe acute respiratory illness, including fever, cough, and shortness of breath. Many of them have died.1,2 MERS-CoV belongs to the coronavirus family, the same family of viruses that cause the common cold. MERS-CoV has so far shown to infect humans, camels, and bats. From camels, it can pass to humans, but how this happens is also unclear. The lack of effective drug treatment and associated high morbidity and mortality rates of coronaviruses as well as their potential to cause epidemics highlight the need for novel drug discovery for the treatment of CoV infections.3 We tried to develop therapeutic agents against newly emerged MERS-CoV, which showed unique phenotype of persistency in the environmental settings, using antibody which can bind with spike proteins of MERS-CoV. We found 2-amino-quinolin-4(1H)-one scaffold after screening 200,000 compounds in Korean Chemical Bank (KCB). This presentation will discuss the synthesis and SAR of 2-amino-quinolin-4(1H)-ones which show good inhibition of infection and high cell viability.

2-Amino-quinolin-4(1H)-ones as novel anti-coronavirus agents

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.